0 Replies
James Watson, co-discoverer of the structure of DNA, says anti-metastatic RNAi is the key to beating cancer.
Sending more government cancer monies towards innovative, anti-metastatic drug development to appropriate high-quality academic institutions would better use National Cancer Institute's (NCI) monies than the large sums spent now testing drugs for which…‘The... Contine Reading & Discuss→
0 Replies
London, UK, 9 March, 2012 Silence Therapeutics plc (AIM: SLN) responds to comments that the Tuschl I (EP 1309726) patent has been upheld in European Opposition Proceedings without any modification. Concluding on 1 March 2012, the European Patent Office held oral opposition hearings in Munich, Germany to discuss the Tuschl... Contine Reading & Discuss→
0 Replies
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, announced today that the United
States Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for patent application number 12/813,448, covering the
company’s proprietary second generation lipid nanoparticle (LNP)
platform, including the “MC3†lipid. This second generation LNP... Contine Reading & Discuss→
1 Reply
--Collaboration to investigate potential application of Silence’s novel AtuPLEX™ and DBTC delivery technologies in the development of novel microRNA therapeutics targeting cancer --
London, UK October XX, 2011 –Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement... Contine Reading & Discuss→
0 Replies
London, September 21, 2011 - Silence Therapeutics plc (AIM: SLN) (“Silence”, the “Group” or the “Company”), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Tony Sedgwick PhD, FRCPath as Chief Business Officer with immediate effect. Dr Sedgwick will be based in Silence’s London office and lead... Contine Reading & Discuss→
0 Replies
-- Collaboration to investigate potential of DACC in intravenous delivery of siRNAs to the lung --
London, UK, September 27, 2011 –Silence Therapeutics plc (AIM: SLN) (“Silence”), a leading RNA interference (RNAi) therapeutics company, today announces that it has entered into an agreement with one of the world’s leading global... Contine Reading & Discuss→
0 Replies
London, September 20, 2011 – Silence Therapeutics plc (AIM: SLN) (“Silence”, the “Group” or the “Company”), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Thomas Christély as Chief Executive Officer with immediate effect. He will be based at Silence’s facility in Berlin.
Thomas Christély (aged... Contine Reading & Discuss→
